Drug intelligence / Profile preview

recombinant COVID-19 variant vaccine

Development stage: Phase 2
Lead developer: WestVac Biopharma
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Inhalation, Intranasal

Overview

This is a recombinant protein subunit vaccine designed to provide acquired immunity against SARS-CoV-2, particularly its variants of concern. It is produced in Sf9 insect cells and comprises the antigen of the tandem receptor-binding domain (RBD) of the viral spike protein. The vaccine elicits specific binding antibody responses to RBD and a robust Th1-mediated interferon-gamma (IFN-γ) production, aiming to stimulate the immune system to recognize and combat the virus.

Brand names: WSK-V102WSK-V-102WSK-V 102
Other names: Recombinant COVID-19 variant vaccine (Sf9 cell)Coviccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on recombinant COVID-19 variant vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant COVID-19 variant vaccine.

Explore the full profile